Takeda Pharmaceutical Co. Ltd.’s oral TYK2 inhibitor zasocitinib (TAK-279) demonstrated statistical superiority over Bristol Myers Squibb Co.’s first-in-class Sotyktu (deucravacitinib) in a top-line phase III Latitude Atlas readout of moderate to severe plaque psoriasis.
More effective glucocorticoid-sparing therapies are needed for the treatment of giant cell arteritis (GCA). Studies found that complement signaling pathways involving complement factor 5 and its receptor (C5aR1) were overexpressed, and that a C5aR1 antagonist, avacopan, reduced the need for glucocorticoids and improved renal recovery. This led researchers to investigate the association of anti-C5aR1 antibodies with GCA and its outcomes.
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone receptor, at the Endocrine Society’s 2026 annual meeting on June 15.
Shanghai Helioson Pharmaceutical Co. Ltd. has patented molecular glue degraders comprising cereblon (CRBN) binding agents acting as proto-oncogene Vav (VAV1) degradation inducers found to be potentially useful for the treatment of autoimmune disease and cancer.
CD45RC is an isoform of protein tyrosine phosphatase receptor type C, a protein that plays a key role in regulating antigen receptor signaling in T and B cells. While it is expressed on most circulating B cells, it is only highly expressed on Th1 precursors, Th1 cells and T effector memory CD45RA+ cells (TEMRA).
Fresh off a deal with Travere Therapeutics Inc. for civorebrutinib worth more than $1.14 billion, Everest Medicines Ltd. went on a shopping spree, striking three deals in six days to expand its pipeline and geographic reach across Asia Pacific.
Therorna Shanghai Co. Ltd. has presented data on TI-0032, an anti-CD19 CAR circular RNA therapeutic delivered by lipid nanoparticles (LNPs) for the treatment of autoimmune and hematological disorders.
Antengene Corp. Ltd. has obtained IND approval from China’s National Medical Products Administration (NMPA) for ATG-201 for the treatment of B-cell related autoimmune diseases.
Kymera Therapeutics has developed KT-579, a potent and selective IRF5 degrader as a novel approach for treating systemic lupus erythematosus (SLE) and Sjögren disease.
Building on its partnerships with Gilead Sciences Inc., Sanofi SA and Pfizer Inc., Nurix Therapeutics Inc. brought on Roche Holding AG to help develop bexobrutideg, an oral degrader of Bruton’s tyrosine kinase (BTK). “I really can’t think of a better partner to maximize the opportunity for bexobrutideg to a wide range of patients,” Jason Kantor, Nurix’s chief business officer, told investors on a conference call, later pointing out that Roche has multiple drugs targeting B cells.
RSS
